These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 19546505)

  • 1. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
    Jones JL; Phuah CL; Cox AL; Thompson SA; Ban M; Shawcross J; Walton A; Sawcer SJ; Compston A; Coles AJ
    J Clin Invest; 2009 Jul; 119(7):2052-61. PubMed ID: 19546505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
    Jones JL; Anderson JM; Phuah CL; Fox EJ; Selmaj K; Margolin D; Lake SL; Palmer J; Thompson SJ; Wilkins A; Webber DJ; Compston DA; Coles AJ
    Brain; 2010 Aug; 133(Pt 8):2232-47. PubMed ID: 20659956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
    von Kutzleben S; Pryce G; Giovannoni G; Baker D
    Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.
    Jones JL; Thompson SA; Loh P; Davies JL; Tuohy OC; Curry AJ; Azzopardi L; Hill-Cawthorne G; Fahey MT; Compston A; Coles AJ
    Proc Natl Acad Sci U S A; 2013 Dec; 110(50):20200-5. PubMed ID: 24282306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating MS: getting to know the two birds in the bush.
    Laufer TM; Wu GF
    J Clin Invest; 2009 Jul; 119(7):1852-3. PubMed ID: 19603540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).
    Walsh M; Chaudhry A; Jayne D
    Ann Rheum Dis; 2008 Sep; 67(9):1322-7. PubMed ID: 18055469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.
    Baker D; Herrod SS; Alvarez-Gonzalez C; Giovannoni G; Schmierer K
    JAMA Neurol; 2017 Aug; 74(8):961-969. PubMed ID: 28604916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis.
    Costelloe L; Jones J; Coles A
    Expert Rev Neurother; 2012 Mar; 12(3):335-41. PubMed ID: 22364332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
    Thompson SA; Jones JL; Cox AL; Compston DA; Coles AJ
    J Clin Immunol; 2010 Jan; 30(1):99-105. PubMed ID: 19763798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on alemtuzumab.
    Jones JL; Coles AJ
    Int MS J; 2009 Sep; 16(3):77-81. PubMed ID: 19878629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
    Hill-Cawthorne GA; Button T; Tuohy O; Jones JL; May K; Somerfield J; Green A; Giovannoni G; Compston DA; Fahey MT; Coles AJ
    J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):298-304. PubMed ID: 22056965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis.
    Hirst CL; Pace A; Pickersgill TP; Jones R; McLean BN; Zajicek JP; Scolding NJ; Robertson NP
    J Neurol; 2008 Feb; 255(2):231-8. PubMed ID: 18283404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
    Chakrabarti S; Hale G; Waldmann H
    Transplant Proc; 2004 Jun; 36(5):1225-7. PubMed ID: 15251298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.
    Cox AL; Thompson SA; Jones JL; Robertson VH; Hale G; Waldmann H; Compston DA; Coles AJ
    Eur J Immunol; 2005 Nov; 35(11):3332-42. PubMed ID: 16231285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
    ; Coles AJ; Compston DA; Selmaj KW; Lake SL; Moran S; Margolin DH; Norris K; Tandon PK
    N Engl J Med; 2008 Oct; 359(17):1786-801. PubMed ID: 18946064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
    Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
    J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.
    Dalakas MC; Rakocevic G; Schmidt J; Salajegheh M; McElroy B; Harris-Love MO; Shrader JA; Levy EW; Dambrosia J; Kampen RL; Bruno DA; Kirk AD
    Brain; 2009 Jun; 132(Pt 6):1536-44. PubMed ID: 19454532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].
    Warnke C; Kieseier BC; Zettl U; Hartung HP
    Nervenarzt; 2009 Apr; 80(4):468-74. PubMed ID: 19296065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.
    Coles AJ; Cox A; Le Page E; Jones J; Trip SA; Deans J; Seaman S; Miller DH; Hale G; Waldmann H; Compston DA
    J Neurol; 2006 Jan; 253(1):98-108. PubMed ID: 16044212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.
    Trzonkowski P; Zilvetti M; Chapman S; Wieckiewicz J; Sutherland A; Friend P; Wood KJ
    Am J Transplant; 2008 Feb; 8(2):338-47. PubMed ID: 18211507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.